Tianjin Tianyao Pharmaceuticals Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 4/6
Tianjin Tianyao Pharmaceuticals's earnings have been declining at an average annual rate of -0.9%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 3.9% per year. Tianjin Tianyao Pharmaceuticals's return on equity is 5.4%, and it has net margins of 4.3%.
Anahtar bilgiler
-0.9%
Kazanç büyüme oranı
-1.1%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 10.9% |
| Gelir büyüme oranı | 3.9% |
| Özkaynak getirisi | 5.4% |
| Net Marj | 4.3% |
| Son Kazanç Güncellemesi | 30 Sep 2024 |
Yakın geçmiş performans güncellemeleri
Gelir ve Gider Dağılımı
Tianjin Tianyao Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Sep 24 | 3,517 | 152 | 1,042 | 169 |
| 30 Jun 24 | 3,561 | 136 | 1,121 | 157 |
| 31 Mar 24 | 3,656 | 108 | 1,223 | 150 |
| 31 Dec 23 | 3,783 | 117 | 1,337 | 158 |
| 30 Sep 23 | 3,815 | 136 | 1,360 | 165 |
| 30 Jun 23 | 3,910 | 98 | 1,435 | 154 |
| 31 Mar 23 | 3,790 | 80 | 1,410 | 153 |
| 31 Dec 22 | 3,689 | 35 | 1,394 | 139 |
| 30 Sep 22 | 3,808 | 47 | 1,426 | 119 |
| 30 Jun 22 | 3,849 | 63 | 1,408 | 128 |
| 31 Mar 22 | 3,792 | 46 | 1,364 | 128 |
| 31 Dec 21 | 3,749 | 49 | 1,385 | 129 |
| 30 Sep 21 | 3,403 | -10 | 1,206 | 142 |
| 30 Jun 21 | 3,201 | -1 | 1,161 | 140 |
| 31 Mar 21 | 3,123 | 19 | 1,089 | 137 |
| 31 Dec 20 | 3,117 | 34 | 1,054 | 132 |
| 30 Sep 20 | 3,005 | 133 | 1,062 | 141 |
| 30 Jun 20 | 3,092 | 143 | 1,057 | 140 |
| 31 Mar 20 | 3,297 | 164 | 1,147 | 140 |
| 31 Dec 19 | 3,327 | 162 | 1,094 | 138 |
| 30 Sep 19 | 3,250 | 163 | 1,011 | 124 |
| 30 Jun 19 | 2,981 | 173 | 918 | 114 |
| 31 Mar 19 | 2,669 | 157 | 828 | 104 |
| 31 Dec 18 | 2,427 | 145 | 802 | 98 |
| 30 Sep 18 | 2,398 | 144 | 812 | 89 |
| 30 Jun 18 | 2,278 | 134 | 678 | 128 |
| 31 Mar 18 | 2,180 | 134 | 560 | 108 |
| 31 Dec 17 | 1,972 | 130 | 401 | 86 |
| 30 Sep 17 | 1,894 | 105 | 314 | 66 |
| 30 Jun 17 | 1,831 | 105 | 352 | 0 |
| 31 Mar 17 | 1,841 | 104 | 374 | 0 |
| 31 Dec 16 | 1,689 | 98 | 327 | 0 |
| 30 Sep 16 | 1,558 | 93 | 264 | 0 |
| 30 Jun 16 | 1,527 | 92 | 228 | 0 |
| 31 Mar 16 | 1,326 | 80 | 134 | 0 |
| 31 Dec 15 | 1,405 | 79 | 136 | 0 |
| 30 Sep 15 | 1,415 | 99 | 124 | 0 |
| 30 Jun 15 | 1,403 | 99 | 122 | 0 |
| 31 Mar 15 | 1,386 | 81 | 118 | 0 |
| 31 Dec 14 | 1,389 | 87 | 114 | 0 |
| 30 Sep 14 | 1,374 | 58 | 126 | 0 |
| 30 Jun 14 | 1,366 | 50 | 118 | 0 |
| 31 Mar 14 | 1,398 | 45 | 114 | 0 |
| 31 Dec 13 | 1,481 | 52 | 118 | 0 |
Kaliteli Kazançlar: 600488 has high quality earnings.
Büyüyen Kar Marjı: 600488's current net profit margins (4.3%) are higher than last year (3.6%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: 600488's earnings have declined by 0.9% per year over the past 5 years.
Büyüme Hızlandırma: 600488's earnings growth over the past year (12.1%) exceeds its 5-year average (-0.9% per year).
Kazançlar vs. Sektör: 600488 earnings growth over the past year (12.1%) exceeded the Pharmaceuticals industry -1.2%.
Özkaynak Getirisi
Yüksek ROE: 600488's Return on Equity (5.4%) is considered low.